Management Team

Kazumi Shiosaki, Ph.D.

President & CEO

Kazumi is the CEO of 28-7, which she co-founded alongside prominent Harvard investigators. She is passionate about creating companies focused on novel and emerging areas of biology. Previously, Kazumi was co-founder and CEO of Mitobridge, a start-up pioneering mitochondrial drugs for muscle and kidney diseases. Mitobridge was acquired by Astellas in 2018. She was also a co-founder and start-up CEO of Epizyme, a leader in novel epigenetic therapeutics, and Primera Diagnostics, a molecular diagnostics company focused on infectious disease and oncology. She has also been a Managing Director at MPM Capital. Kazumi started her career at Abbott and rose through the ranks at Millennium to become SVP of Drug Discovery. She is presently a board member of the Sanford Burnham Institute. Kazumi received her Ph.D. in Synthetic Chemistry from UC Berkeley.

Shomir Ghosh, Ph.D.

Chief Scientific Officer

Shomir has 25 years’ of leadership in drug discovery and development at multiple biotechs and big pharmas. Most recently, he was the CSO of IFM Therapeutics, where he built an international drug discovery and discovery biology research team focused on targeting the innate immune system to treat cancer and inflammation. IFM was acquired by Bristol Myers Squibb in 2017. Prior to IFM, he was an Entrepreneur-in-Residence at Atlas Venture, where he evaluated and advised biotech start-ups, including Nimbus, Navitor, and F-Star. Prior to IFM, he held roles of increasing responsibility at Tempero, Epix, Millennium, Leukosite and Abbott. His efforts have led to novel compounds in immunology, immuno-oncology, oncology, and neuroscience. Shomir obtained his Ph.D. in Medicinal Chemistry from the University of Kansas and completed a postdoctoral fellowship in Bioorganic and Medicinal Chemistry at Parke-Davis. He is a co-author and co-inventor on over 80 papers and patent applications and has 43 issued patents.

Ross Stein, Ph.D.

Executive Vice President, Research

Ross Stein is Executive Vice President of Research at Twentyeight-Seven.  Dr. Stein’s career has included positions at Merck, where he headed the Enzymology Department, and ProScript (acquired by Millennium in 1999) as VP, Biochemistry.  At ProScript, Dr. Stein was instrumental in the pre-clinical development and co-inventor of the drug Velcade.  Leaving ProScript, he co-founded and ran the Laboratory for Drug Discovery in Neurodegeration at Harvard Medical School, after which he became VP, Discovery Research at Sirtris Pharmaceuticals.  Stein has published over 100 papers in peer-reviewed journals, as well as a textbook on the kinetics of enzyme action. Ross received his Ph.D. in Physical Organic Chemistry at Indiana University.

Bob Campbell, Ph.D.

Senior Vice President, Biological and Translational Sciences

Robert “Bob” Campbell is Senior Vice President of Biological and Translational Sciences at Twentyeight-Seven. Over the span of his career, Bob has held positions of increasing responsibility in both biotech (Cadus Pharmaceuticals) and large pharma (Hoffmann-La Roche, Eli Lilly & Company). Notably, Bob was key in establishing Lilly’s kinase platform which produced a number of clinical candidates including Verzenio (approved in 2017). Later on, Bob directed the Lilly Novel Target Validation group exploring mechanisms of innate and acquired resistance in oncology. He has published over 130 papers in peer-reviewed journals and books. Bob currently serves as the Editor-in-Chief of SLAS Discovery and is a member of the editorial board for Molecular Cancer Therapeutics. He received his Ph.D. in Biochemistry from Rutgers University.

Edward Darr

Vice President, Finance & Operations

Edward Darr is the Director of Finance and Operations at Twentyeight-Seven.  Ed began his career on the audit staff of Ernst & Whinney (now E&Y) and has over 25 years’ experience managing finance and operations teams. In addition to senior finance positions at Mercer and AECOM, Ed has served as the CFO of several firms in the architecture, civil engineering, and environmental science fields. Ed is a licensed CPA and a member of the AICPA and the VSCPA, and received a BBA in Finance from the University of Notre Dame.


George Daley, M.D., Ph.D.

Dean of the Faculty of Medicine // Professor of Medicine, Biological Chemistry and Molecular Pharmacology, Harvard Medical School

Richard Gregory, Ph.D.

Professor of Biological Chemistry and Molecular Pharmacology, and Pediatrics, Harvard Medical School // Co-Director, HMS Initiative for RNA Medicine

Frank Slack, Ph.D.

Professor of Pathology, Harvard Medical School // Director of Institute of RNA Medicine, Beth Israel Deaconess Medical Center

Piotr Sliz, Ph.D.

Associate Professor of Pediatrics and of Biological Chemistry and Molecular Pharmacology, Harvard Medical School // Director of Research Information, Boston Children’s Hospital

Board of Directors

Luke Evnin, Ph.D.

Managing Director and co-founder, MPM Capital

Briggs Morrison, M.D.

Executive Partner, MPM Capital; CEO, Syndax

Marian Nakada, Ph.D.

VP - Venture Investments, Johnson & Johnson Innovation

Carolyn Ng, Ph.D.

Managing Director, Vertex Ventures HC

Henrijette Richter, Ph.D.

Managing Partner, Sofinnova Partners

Michal Silverberg, M.B.A.

Managing Director, Novartis Venture Fund

Kazumi Shiosaki, Ph.D.

President and CEO, Twentyeight-Seven

Our Team